ATYR PHARMA INC (LIFE) Stock Price, Forecast & Analysis
USA - NASDAQ:LIFE - US0021202025 - Common Stock
LIFE Key Statistics, Chart & Performance
The current stock price of LIFE is 1.9 USD. In the past month the price increased by 14.46%. In the past year, price decreased by -13.64%.
LIFE Latest News, Press Relases and Analysis
LIFE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.76 | 388.47B | ||
| AMGN | AMGEN INC | 13.55 | 159.08B | ||
| GILD | GILEAD SCIENCES INC | 14.53 | 147.68B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.97 | 108.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.58 | 69.58B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 345.45 | 58.87B | ||
| ARGX | ARGENX SE - ADR | 61.68 | 50.32B | ||
| INSM | INSMED INC | N/A | 40.41B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.99 | 33.95B | ||
| NTRA | NATERA INC | N/A | 27.14B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.76B | ||
| BIIB | BIOGEN INC | 9.15 | 22.45B |
Related stock screener links
About LIFE
Company Profile
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. The company is headquartered in San Diego, California and currently employs 65 full-time employees. The company went IPO on 2015-05-07. The Company’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. The Company’s primary focus is efzofitimod, a clinical-stage product candidate, which targets neuropilin-2 (NRP2) to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a mechanism of action for potentially treating lung inflammation and fibrosis. Its lead indication for efzofitimod is pulmonary sarcoidosis, a major form of interstitial lung disease. Its other product candidates include ATYR2810, NRP2 mAbs, AARS and DARS. ATYR2810 is a product candidate from its NRP2 antibody program. The company is also advancing its preclinical pipeline of tRNA synthetases and NRP2. The company has also advanced its preclinical pipeline of NRP2 targeting antibody candidates.
Company Info
ATYR PHARMA INC
10240 Sorrento Valley Road, Suite 300
San Diego CALIFORNIA 92121 US
CEO: Sanjay S. Shukla
Employees: 65
Phone: 18587318389
ATYR PHARMA INC / LIFE FAQ
What does ATYR PHARMA INC do?
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. The company is headquartered in San Diego, California and currently employs 65 full-time employees. The company went IPO on 2015-05-07. The Company’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. The Company’s primary focus is efzofitimod, a clinical-stage product candidate, which targets neuropilin-2 (NRP2) to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a mechanism of action for potentially treating lung inflammation and fibrosis. Its lead indication for efzofitimod is pulmonary sarcoidosis, a major form of interstitial lung disease. Its other product candidates include ATYR2810, NRP2 mAbs, AARS and DARS. ATYR2810 is a product candidate from its NRP2 antibody program. The company is also advancing its preclinical pipeline of tRNA synthetases and NRP2. The company has also advanced its preclinical pipeline of NRP2 targeting antibody candidates.
What is the current price of LIFE stock?
The current stock price of LIFE is 1.9 USD. The price increased by 2.7% in the last trading session.
Does ATYR PHARMA INC pay dividends?
LIFE does not pay a dividend.
What is the ChartMill technical and fundamental rating of LIFE stock?
LIFE has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is LIFE stock listed?
LIFE stock is listed on the Nasdaq exchange.
What is the analyst forecast for LIFE stock?
11 analysts have analysed LIFE and the average price target is 25.09 USD. This implies a price increase of 1220.63% is expected in the next year compared to the current price of 1.9.
Can you provide the market cap for ATYR PHARMA INC?
ATYR PHARMA INC (LIFE) has a market capitalization of 129.87M USD. This makes LIFE a Micro Cap stock.
LIFE Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to LIFE. When comparing the yearly performance of all stocks, LIFE turns out to be only a medium performer in the overall market: it outperformed 56.36% of all stocks.
LIFE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LIFE. Both the profitability and financial health of LIFE have multiple concerns.
LIFE Financial Highlights
Over the last trailing twelve months LIFE reported a non-GAAP Earnings per Share(EPS) of -0.9. The EPS increased by 37.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -47.62% | ||
| ROE | -63.85% | ||
| Debt/Equity | 0.02 |
LIFE Forecast & Estimates
11 analysts have analysed LIFE and the average price target is 25.09 USD. This implies a price increase of 1220.63% is expected in the next year compared to the current price of 1.9.
For the next year, analysts expect an EPS growth of 2.52% and a revenue growth -19.38% for LIFE